USFDA approval for Orchid
By Our Corporate Bureau | 05 Dec 2003
Chennai: Orchid Chemicals & Pharmaceuticals, a city-based bulk drug major, has formally received the approval from the United States Food and Drugs Administration (USFDA) for its sterile API (active pharmaceutical ingredient) product Cefazolin.
The USFDA authorities inspected the plant this September. An important sterile cephalosporin antibiotic API, Cefazolin is used in the treatment of several infections. Orchid has established world-class sterile lyophilisation and non-sterile facilities for integrated manufacture of this product.
"This is definitely a very key development for Orchid and another significant milestone in our regulatory roadmap. This approval will enable a strong entry for our sterile injectable product, Cefazolin, into the US market. We hope to start exports of this product to the US soon," says Orchid managing director Raghavendra Rao.
Latest articles
Featured articles
The decoupling paradox: Why Wall Street keeps funding AI despite $100 oil
By Axel Miller | 11 May 2026
AI infrastructure stocks continue rallying despite $100 oil as investors bet on productivity gains and semiconductor demand in 2026.
Hybrid bonding gains attention as AI chip packaging demand grows
By Cygnus | 23 Apr 2026
Hybrid bonding is driving AI chip packaging demand as backend technologies gain importance in the semiconductor supply chain.
The agentic transition: how enterprises are scaling AI from pilot to profit
By Cygnus | 22 Apr 2026
AI has entered its execution era. Discover how companies like Valeo and Microsoft are scaling agentic AI systems—from copilots to autonomous workflows driving real business impact.
Post-splashdown: What Artemis II taught us about the ‘deep space wall’
By Axel Miller | 15 Apr 2026
Artemis II splashdown marks a breakthrough in deep space exploration. Discover AVATAR radiation data, Orion’s distance record, and insights shaping NASA’s 2028 Moon mission.
Can aviation go green? The multi-billion dollar race for sustainable fuel
By Cygnus | 10 Apr 2026
Airlines are racing to adopt sustainable aviation fuel, but limited supply and high costs challenge the future of green aviation.
The battery race: who will control the future of electric vehicles?
By Axel Miller | 08 Apr 2026
The global battery race is reshaping the electric vehicle industry, with China, the US, and Europe competing for control over supply chains and technology.
AI vs governments: Who controls the future of intelligence?
By Cygnus | 07 Apr 2026
Governments and AI companies like OpenAI and Anthropic are shaping the future of intelligence amid rising policy conflicts and global competition.
Strait of Hormuz: how one chokepoint controls the global economy
By Axel Miller | 06 Apr 2026
The Strait of Hormuz is a critical global chokepoint. Learn how disruptions impact oil prices, shipping, and the global economy.
The $2 trillion AI infrastructure race: Who will control global compute?
By Cygnus | 06 Apr 2026
AI spending is set to exceed $2 trillion in 2026, driving a global race in data centers, chips, and energy infrastructure.
Latest articles
